$AKRX(.20) has Many FDA approved drugs! 2019 Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% read more... 2018 Akorn Receives FDA Approval for Diclofenac Sodium Topical Gel, 1% read more... Akorn Receives FDA Approval for Clobetasol Propionate Lotion, 0.05% read more... Akorn Receives FDA Approval for Bimatoprost Ophthalmic Solution, 0.03% read more... 2017 Akorn Receives FDA Approval for Mycophenolate Mofetil for Injection, USP read more... 2015 Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution read more... 2014 Akorn Acquires Xopenex® (levalbuterol HCI) Inhalation Solution read more... Akorn Acquires Hi-Tech Pharmacal. read more... Akorn Acquires VersaPharm. read more... 2013-2014 Akorn Acquires Four Branded Ophthalmic Products: Zioptan®, CosoptPF/Cosopt®, AzaSite®, and Betimol®. 2012 Generic Vancocin® is approved and launched. 2011 Advanced Consumer Health is acquired to expand presence in a $1.2 billion over-the-counter eye care market. read more... A Minority Stake in Aciex Therapeutics is acquired providing access to an innovative ophthalmic pipeline. read more... Entered into agreement to acquire assets from Kilitch Drugs of India to expand manufacturing of sterile injectables and global reach. read more... Nembutal®, a Schedule II controlled drug, Diuril® and Cogentin® are acquired from Lundbeck Pharma. 2010 The Akorn R&D Center in Skokie, IL is opened to provide leading edge capabilities for the development of new and generic pharmaceuticals. 2008 Corporate Headquarters are moved to Lake Forest, Illinois. Warehousing is relocated to Gurnee, Illinois. Akten® (lidocaine HCI ophthalmic gel) 3.5%, Akorn's first internally developed NDA indicated for topical ocular anesthesia is launched. 2007 Akorn, Inc. is listed on the NASDAQ exchange. 2004 Akorn Inc. and Strides Arcolab Ltd. enter into a joint venture as Akorn-Strides, LLC. 2002 Paremyd® (hydroxyamphetamine hydrobromide and tropicamide, ophthalmic solution), a convenient one-drop dilation agent is launched. 1998 Advanced Remedies Incorporated is acquired in Somerset, New Jersey, a division of Sidmak laboratories and manufacturer of sterile ophthalic ointments and solutions. 1997 Akorn Inc. is founded. Corporate headquarters and distribution offices are moved to Buffalo Grove, Illinois. Indocyanine green, now IC-Green®, Akorn's first New Drug Application (NDA) ophthalmic drug for retina diagnostic imaging, is acquired from Becton Dickinson (BD). 1996 Taylor Pharmacal Company begins operating under the name of Akorn Manufacturing. Pasadena Research Laboratories in Pasadena, California is acquired along with its injectable line of products. 1994 The Grand facility in Decatur is expanded to add ophthalmic filling operations. 1992 The Taylor family sells Taylor Pharmacal Company to Akorn Inc., a Louisiana based ophthalmic sales and distribution company, that owns ophthalmic products under the Akorn Ophthalmics label. 1977 The Wyckles facility in Decatur, Illinois is constructed to provide packaging and warehouse operation and to allow expansion of the filling and laboratory testing areas at the Grand facility. 1971 Akorn Ophthalmics is founded in Abita Springs, Louisiana 1953 The Grand facility in Decatur, Illinois is constructed to provide a filling and packaging location for the manufacture of pharmaceutical products. 1948 Taylor Pharmacal is founded by Guy Taylor and his two sons in Decatur Illinois.
News 
Market Data 
Discover 
